A meta-analysis of three clinical trials, comparing the frequency of AKI adverse events in T2DM patients treated with placebo or an SGLT2 inhibitor, reported that SGLT2 inhibitors may protect vulnerable patients with T2DM from AKI [6]. Here, SLC5A2 is linked to type 2 diabetes mellitus.